This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Importance of Asking the Right Questions

Alastair J. J. Wood, MD

JAMA. 1999;281:1753-1754.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article in this issue of The Journal by Friedman and colleagues¹ at the US Food and Drug Administration (FDA) explores the important question: "Has the number of drug withdrawals increased since the passage of the Prescription Drug User Fee Act?" This question was stimulated by an apparent spate of recent removals—5 drugs in 1 year. However, when the data were analyzed, not by the year of drug removal but by the year of drug entry into the market, the clustering of cases was not apparent. This finding is reassuring as it does not support previous criticism of the changes that followed the passage of the legislation. The rejection of 1 hypothesis should be viewed as a challenge to the scientific community and the FDA to enter into a public discussion to define what can be learned from the removal of these drugs and can . . . [Full Text of this Article]

Author Affiliation: Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tenn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Michael A. Friedman, Janet Woodcock, Murray M. Lumpkin, Jeffrey E. Shuren, Arthur E. Hass, and Larry J. Thompson
JAMA. 1999;281(18):1728-1734.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Proposal for Radical Changes in the Drug-Approval Process
Wood
NEJM 2006;355:618-623.
FULL TEXT  

Smart Regulation: Will the government's strategy work?
Graham
CMAJ 2005;173:1469-1470.
FULL TEXT  

Responding to the Rofecoxib Withdrawal Crisis: A New Model for Notifying Patients at Risk and Their Health Care Providers
Jain et al.
ANN INTERN MED 2005;142:182-186.
ABSTRACT | FULL TEXT  

Gaps, Tensions, and Conflicts in the FDA Approval Process: Implications for Clinical Practice
Deyo
J Am Board Fam Med 2004;17:142-149.
ABSTRACT | FULL TEXT  

Timing of New Black Box Warnings and Withdrawals for Prescription Medications
Lasser et al.
JAMA 2002;287:2215-2220.
ABSTRACT | FULL TEXT  

Clopidogrel and Thrombotic Thrombocytopenic Purpura
Salliere et al.
NEJM 2000;343:1191-1194.
FULL TEXT  

Thrombotic Thrombocytopenic Purpura and Clopidogrel -- A Need for New Approaches to Drug Safety
Wood
NEJM 2000;342:1824-1826.
FULL TEXT